Board of Directors and Management

Management

Ulf Bladin CEO

CEO since 1 July 2020. 

Ulf Bladin is a Bachelor of Medicine from Karolinska Institutet, holds a Master of Business Administration and an MSc from the Stockholm School of Economics. Ulf has previously been General Manager, Vice President of the EMEA region at Hycor Biomedical, Vice President Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division, and Vice President with Global Responsibility for Marketing, Health Economy, Corporate Communications, Scientific & Regulatory Affairs at Phadia. He has also held leading commercial positions in the pharmaceutical industry at Pfizer and Merck Sharp & Dohme. Board member of Lumito AB.

Shareholding: 724 638 shares, 724 638 TO4, 724 638 TO5.

Henrik Ljung CFO

Education and background: Henrik Ljung has a master's degree in economics from Lund University. He has a solid background as a chartered accountant and many years of experience as a CFO in listed companies, such as Acconeer AB, Carbiotix AB and Qlife Holding AB, and AB Sardus. Henrik has extensive experience of companies in an early stage of development, as well as company acquisitions.

Shareholding: 0

Tobias Volker Acting Head of Subsidiary Psyros Diagnostics

Education and background: PhD in Biochemistry and an MBA from INSEAD. Over the last decades, Volker has strongly contributed to the development of point-of-care for heart disease but also in other disease areas. At Biosite, he led the international development of the Triage platform and launched the cardiac panel and the very first reimbursable BNP assay in Europe. Responsible for the launch of Quo-Test HbA1c at Quotient Diagnostics and participated in the reverse acquisition that later became EKF Diagnostics. Volker gained further insight into the POC business while working at Cholestech, Alere and more recently at Expand Healthcare Consulting GmbH, where he was a high-level advisor to private companies and non-profit organizations. He has also been the responsible manager of the healthcare R&D group at SK Telecom (now Invites Healthcare).

Chairman of the Board of Expand Healthcare Consulting GmbH and member of the Board of Ominilabs.

Number of shares as of May 27, 2022: 542,518

Board of Directors

Masoud Khayyami Chairman of the board

Education and background: PhD in Pure and Applied Biochemistry at Lund University. Solid experience from research, medicine, medtech and the biotechnology sectors. Solid entrepreneurial experience (e.g. Prolight Diagnostics AB, Lumito AB and Gasporox AB) and an expert in applied medicine, microbiology and biotech, especially in the development of different types of biomolecules for commercial use and research in biological applications. Board member in both medtech companies and other companies. Engaged in Prolight Diagnostics since 1999, and founder of the company.

Shareholding: 2 056 812 shares via Khayyami Invest AB.

Maria Holmlund Board Member

Education and background: Bachelor's Degree in Chemistry and Biology from Uppsala University and a Master of Science from the University of North Carolina. 30 years of experience in the life science and diagnostics field. Worked in senior positions with a focus on marketing in international diagnostics companies such as Pharmacia Diagnostics, Boehringer Mannheim, Roche Scandinavia, Phadia and Thermo Fisher Scientific. Board member of Biovica AB. CEO of Prolight Diagnostics AB between 2016-2020.

Number of shares as of April 22, 2022: 361,404. 154,887 TO4, 154,887 TO5

Ulf Bladin CEO and Board Member

Ulf Bladin is a Bachelor of Medicine from Karolinska Institutet, holds a Master of Business Administration and an MSc from the Stockholm School of Economics. Ulf has previously been General Manager, Vice President of the EMEA region at Hycor Biomedical, Vice President Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division, and Vice President with Global Responsibility for Marketing, Health Economy, Corporate Communications, Scientific & Regulatory Affairs at Phadia. He has also held leading commercial positions in the pharmaceutical industry at Pfizer and Merck Sharp & Dohme. Board member of Lumito AB.

Shareholding: 724 638 shares, 724 638 TO4, 724 638 TO5.

Steve Ross Board member

Education and background: Steve Ross has two undergraduate degrees, one in chemistry, the other in mathematics with statistics, and he received his PhD from Edinburgh University in synthetic chemistry. He subsequently carried out postdoctoral research at The University of Utah (Royal Society Fellowship), the CNRS in Toulouse, France (Marie Curie Fellowship) and The University of Oxford.

Steve Ross is a co-founder of Psyros and has worked in in-vitro diagnostics for over 15 years. His industrial career started in 2001 with PiezOptic, developing pyroelectric sensors for monitoring exposure to toxic gases. In 2006 he co-founded Vivacta, a start-up company using the same pyroelectric technology, this time for point-of-care clinical diagnostics.

Number of shares as of March 22, 2022: 8,290,816 

Aileen McGettrick Board member

Education and background: PhD in biochemistry and genetics at Oxford University followed by Postdoctoral Research Fellowships at Oxford and the Joslin Diabetes Center, Boston USA (affiliated to Harvard Medical School) researching the genetics of Type 2 diabetes.

Aileen McGettrick is co-founder of Psyros and has 15 years of experience in assay development for medical devices. From 2008 to 2018 in her role as Group Head of Assay Development she led multi-disciplinary teams for VC backed start-up Vivacta Ltd and subsequently the Novartis Near Patient Testing Unit (after acquisition of Vivacta by Novartis in 2012), specializing in detection of target analytes in whole blood for point of care diagnostics. With a broad working knowledge of the regulatory requirements for medical devices she brings strong operational and project management skills to the team.

Number of shares as of March 31, 2022: 8,290,816

Tobias Volker Board member

Education and background: PhD in Biochemistry and an MBA from INSEAD. Over the last decades, Volker has strongly contributed to the development of point-of-care for heart disease but also in other disease areas. At Biosite, he led the international development of the Triage platform and launched the cardiac panel and the very first reimbursable BNP assay in Europe. Responsible for the launch of Quo-Test HbA1c at Quotient Diagnostics and participated in the reverse acquisition that later became EKF Diagnostics. Volker gained further insight into the POC business while working at Cholestech, Alere and more recently at Expand Healthcare Consulting GmbH, where he was a high-level advisor to private companies and non-profit organizations. He has also been the responsible manager of the healthcare R&D group at SK Telecom (now Invites Healthcare).

Chairman of the Board of Expand Healthcare Consulting GmbH and member of the Board of Ominilabs.

Number of shares as of May 27, 2022: 542,518